Cremeomycin, with the CAS number 11050-22-9, is an antibiotic compound that belongs to the class of macrolide antibiotics. It is produced by the fermentation of certain strains of Streptomyces bacteria. Cremeomycin exhibits antibacterial properties, primarily targeting Gram-positive bacteria, and is known for its effectiveness against various infections. The compound works by inhibiting protein synthesis in bacterial cells, thereby preventing their growth and replication. In terms of its chemical structure, cremeomycin features a large lactone ring, characteristic of macrolides, which contributes to its biological activity. It is typically administered in clinical settings for the treatment of specific bacterial infections, although its use may be limited due to the emergence of antibiotic resistance. As with many antibiotics, potential side effects can include gastrointestinal disturbances and allergic reactions. Overall, cremeomycin represents an important tool in the antibiotic arsenal, particularly in the context of treating infections caused by susceptible bacterial strains.

cremeomycin

11050-22-9: Cremeomycin, with the CAS number 11050-22-9, is an antibiotic compound that belongs to the class of macrolide antibiotics. It is produced by the fermentation of certain strains of Streptomyces bacteria. Cremeomycin exhibits antibacterial properties, primarily targeting Gram-positive bacteria, and is known for its effectiveness against various infections. The compound works by inhibiting protein synthesis in bacterial cells, thereby preventing their growth and replication. In terms of its chemical structure, cremeomycin features a large lactone ring, characteristic of macrolides, which contributes to its biological activity. It is typically administered in clinical settings for the treatment of specific bacterial infections, although its use may be limited due to the emergence of antibiotic resistance. As with many antibiotics, potential side effects can include gastrointestinal disturbances and allergic reactions. Overall, cremeomycin represents an important tool in the antibiotic arsenal, particularly in the context of treating infections caused by susceptible bacterial strains.

<p>Cremeomycin exhibits activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), with a minimum inhibitory concentration (MIC) of 0.2-0.39 μg/mL. It also demonstrates cytotoxic effects in vitro against mouse tumor cell lines P388, L1210, IMC, S180, B16, and SS3.</p>

CAS 11050-22-9

cremeomycin

Cremeomycin

Ref: TM-TN10019